SG11201903628TA - Hyperpolarized [3- 13c]acetoacetate and methods of using the same - Google Patents
Hyperpolarized [3- 13c]acetoacetate and methods of using the sameInfo
- Publication number
- SG11201903628TA SG11201903628TA SG11201903628TA SG11201903628TA SG11201903628TA SG 11201903628T A SG11201903628T A SG 11201903628TA SG 11201903628T A SG11201903628T A SG 11201903628TA SG 11201903628T A SG11201903628T A SG 11201903628TA SG 11201903628T A SG11201903628T A SG 11201903628TA
- Authority
- SG
- Singapore
- Prior art keywords
- acetoacetate
- international
- hyperpolarized
- diseases
- singapore
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/716—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
- C07C69/72—Acetoacetic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date ill Hu omits 1E1 0 0111111 EMI DOI IMMO 011 (10) International Publication Number WO 2018/080394 Al 03 May 2018 (03.05.2018) WIP0 I PCT (51) International Patent Classification: A61K 49/10 (2006.01) (21) International Application Number: PCT/SG2017/050518 (22) International Filing Date: 16 October 2017 (16.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 10201609057Q 28 October 2016 (28.10.2016) SG (71) Applicant: AGENCY FOR SCIENCE, TECHNOLO- GY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG). (72) Inventor: LEE, Teck Hock; c/o Singapore Bioimaging Consortium, 11 Biopolis Way, #02-02, Singapore 138667 (SG). (74) Agent: VIERING, JENTSCHURA & PARTNER LLP; P.O. Box 1088, Rochor Post Office, Rochor Road, Singa- pore 911833 (SG). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) 1-1 71. (54) Title: HYPERPOLARIZED [3- 13 C]ACETOACETATE AND METHODS OF USING THE SAME 01 (57) : The present invention relates to hyperpolarized [3- 13 C]acetoacetate. Provided are [3- C]acetoacetate and compositions 13 GP comprising said [3- C]acetoacetate. Further provided are methods of preparing and using hyperpolarized [3- C]acetoacetate in the 13 13 determination of the spatial and temporal distribution and metabolism of [3- C]acetoacetate and/or its metabolites in a cell or subject, 13 *t preferably by magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), and/or magnetic resonance spectroscopic 1-1 cz imaging (MRSI), whereby conditions, diseases, or disorders associated with the metabolism of acetoacetate and/or other ketone bodies ei can be diagnosed. The conditions, diseases, or disorders to be diagnosed preferably are cancer, diabetes, cardiovascular diseases, or 0 neurodegenerative diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201609057Q | 2016-10-28 | ||
| PCT/SG2017/050518 WO2018080394A1 (en) | 2016-10-28 | 2017-10-16 | Hyperpolarized [3- 13c]acetoacetate and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903628TA true SG11201903628TA (en) | 2019-05-30 |
Family
ID=62025332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903628TA SG11201903628TA (en) | 2016-10-28 | 2017-10-16 | Hyperpolarized [3- 13c]acetoacetate and methods of using the same |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10995054B2 (en) |
| EP (1) | EP3544639A4 (en) |
| SG (1) | SG11201903628TA (en) |
| WO (1) | WO2018080394A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020205544A1 (en) * | 2019-03-29 | 2020-10-08 | Cary Douglas D | Use of ketone bodies medical imaging and diagnostics |
| EP4090648A1 (en) * | 2020-01-17 | 2022-11-23 | The Government of The United States of America as represented by The Secretary, Department of Health and Human Services | Isotopes of alpha ketoglutarate and related compounds and their use in hyperpolarized imaging |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102892434B (en) * | 2010-04-08 | 2014-11-19 | 伯拉考成像股份公司 | Process for preparing hyperpolarized substrates and method for mri |
| CN104981256B (en) * | 2013-01-31 | 2020-02-18 | 伯拉考成像股份公司 | Hyperpolarised esters as metabolic markers in MR |
-
2017
- 2017-10-16 WO PCT/SG2017/050518 patent/WO2018080394A1/en active Search and Examination
- 2017-10-16 SG SG11201903628TA patent/SG11201903628TA/en unknown
- 2017-10-16 US US16/345,641 patent/US10995054B2/en active Active
- 2017-10-16 EP EP17863314.5A patent/EP3544639A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3544639A4 (en) | 2020-07-08 |
| US20190270693A1 (en) | 2019-09-05 |
| US10995054B2 (en) | 2021-05-04 |
| EP3544639A1 (en) | 2019-10-02 |
| WO2018080394A1 (en) | 2018-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909344SA (en) | Anti-lag3 antibodies | |
| SG11201903331QA (en) | Restimulation of cryopreserved tumor infiltrating lymphocytes | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201907561PA (en) | Anti-lag-3 antibodies and uses thereof | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201810872UA (en) | Composition and method for reducing neutropenia | |
| SG11201901628XA (en) | Methods and compositions for spinal cord cells | |
| SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
| SG11201908127WA (en) | Method for producing multispecific antibodies | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201804412SA (en) | Dimeric contrast agents | |
| SG11201909501TA (en) | Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201807478QA (en) | Methods and compositions for increased double stranded rna production | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201906778RA (en) | Improved methods for assessing risk of developing breast cancer | |
| SG11201806432PA (en) | Methods for assessing risk of developing colorectal cancer | |
| SG11201900636WA (en) | Aluminum alloy products, and methods of making the same |